On 12/31/2024, SING GEORGE L, associated with Regeneron Pharmaceuticals, exercised options to acquire 3,338 shares of Common Stock at $413.33 per share. Simultaneously, 1,948 shares were disposed of at $708.19 each, totaling $1,379,554.12, likely for tax liability purposes.Following these transactions, SING GEORGE L directly owned 27,662 shares. On 01/02/2025, an additional 166 shares were granted at no cost, bringing the direct ownership to 27,828 shares. The reporting person also indirectly owns 2,150 shares through various family arrangements.These transactions are part of an ongoing series, with the earliest reported date being 12/31/2024 and the latest 01/02/2025. The mix of option exercises, share disposals, and new grants suggests a typical pattern of executive compensation management and potential tax strategy implementation.

On 12/31/2024, SING GEORGE L, associated with Regeneron Pharmaceuticals, exercised options to acquire 3,338 shares of Common Stock at $413.33 per share. Simultaneously, 1,948 shares were disposed of at $708.19 each, totaling $1,379,554.12, likely for tax liability purposes.Following these transactions, SING GEORGE L directly owned 27,662 shares. On 01/02/2025, an additional 166 shares were granted at no cost, bringing the direct ownership to 27,828 shares. The reporting person also indirectly owns 2,150 shares through various family arrangements.These transactions are part of an ongoing series, with the earliest reported date being 12/31/2024 and the latest 01/02/2025. The mix of option exercises, share disposals, and new grants suggests a typical pattern of executive compensation management and potential tax strategy implementation.